Idiopathic pulmonary fibrosis (IPF) is characterized by progressive fibroblast and
myofibroblast proliferation, and extensive deposition of extracellular matrix (ECM). Fibroblast …

Idiopathic pulmonary fibrosis (IPF) is a progressive and lethal lung disease characterized by
the expansion of the fibroblast/myofibroblast population and aberrant remodeling. However …

Idiopathic pulmonary fibrosis (IPF) is characterized by progressive pulmonary scarring,
decline in lung function, and often results in death within 3–5 five years after diagnosis …

Idiopathic pulmonary fibrosis (IPF) is characterized by an accumulation of extracellular
matrix proteins and fibroblasts in the distal airways. Key developmental lung signaling …

Fibroblast growth factor (FGF) signaling has been implicated in the pathogenesis of
pulmonary fibrosis. Mice lacking FGF2 have increased mortality and impaired epithelial …

Background Recent clinical studies show that tyrosine kinase inhibitors slow the rate of lung
function decline and decrease the number of acute exacerbations in patients with Idiopathic …

Idiopathic Pulmonary Fibrosis (IPF) is characterized by injury and loss of lung epithelial
cells, accumulation of fibroblasts/myofibroblasts and abnormal remodeling of the lung …

Although most evident in the skin, the process of scarring, or fibrosis, occurs in all major
organs because of impaired epithelial self‐renewal. No current therapy exists for Idiopathic …

Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease with limited therapeutic
possibilities. FGF19 (fibroblast growth factor 19), an endocrine FGF, was recently shown to …

Although it is recognized that three isoforms of transforming growth factor-beta (TGF-beta)
exist in mammals, their expression, distribution, and function in injury and repair are not well …